Drug facts
MoleculeGabapentin (Neurontin)
Generics already compete: 27 makers on the market. 104 A-rated products from 27 makers substitute at the counter.
Neurontin was first approved by the FDA on 12/30/1993 under NDA 020235; the application holder is Viatris Specialty LLC.
The latest NADAC for GABAPENTIN 600 MG TABLET is $0.06 per unit (as of 10/28/2026).
Holder Viatris Specialty LLCApplication NDA 020235Approved 12/30/1993
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Neurontin patent listed in the Orange Book Orange Book
02Competition
- Generics
- 27 generic makers Orange Book
- First generic approved
- 09/12/2003 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Gabapentin profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.06 per unitGABAPENTIN 600 MG TABLET, as of 10/28/2026 CMS NADAC
- Latest recall
- 10/10/2025Class II, Gabapentin, The Harvard Drug Group LLC FDA enforcement
04Product
- Application holder
- Viatris Specialty LLC Orange Book
- Application
- NDA 020235 Orange Book
- First approved
- 12/30/1993 Orange Book
- Dosage forms
- capsule; solution; tablet
- Routes
- oral
- Other brand names
- GraliseRelgaabi
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.